Employment |
No Relationships to Disclose |
|
|
Leadership |
Company: Precision Biosensors |
Recipient: You |
|
Stock and Other Ownership Interests |
Company: Elicio Therapeutics |
Recipient: You |
|
Honoraria |
No Relationships to Disclose |
|
|
Consulting or Advisory Role |
Company: Natera |
Recipient: You |
Company: Foundation Medicine |
Recipient: You |
Company: MSD Oncology |
Recipient: You |
Company: Tempus |
Recipient: You |
Company: Bayer |
Recipient: You |
Company: Lilly |
Recipient: You |
Company: Delcath Systems |
Recipient: You |
Company: QED Therapeutics |
Recipient: You |
Company: SERVIER |
Recipient: You |
Company: Taiho Oncology |
Recipient: You |
Company: Exact Sciences |
Recipient: You |
Company: Daiichi Sankyo/Astra Zeneca |
Recipient: You |
Company: Eisai |
Recipient: You |
Company: Seattle Genetics |
Recipient: You |
Company: SAGA Diagnostics |
Recipient: You |
Company: Illumina |
Recipient: You |
Company: BostonGene |
Recipient: You |
Company: NeoGenomics Laboratories |
Recipient: You |
Company: Elicio Therapeutics |
Recipient: You |
Company: BostonGene |
Recipient: You |
Company: Guardant Health |
Recipient: You |
Company: Regeneron |
Recipient: You |
Company: BeiGene |
Recipient: You |
Company: Xilio Therapeutics |
Recipient: You |
Company: Astellas Pharma |
Recipient: You |
Company: Taiho Pharmaceutical |
Recipient: Your Institution |
Company: Ipsen |
Recipient: Your Institution |
|
Speakers' Bureau |
No Relationships to Disclose |
|
|
Research Funding |
Company: Advanced Accelerator Applications |
Recipient: Your Institution |
Company: Tersera |
Recipient: Your Institution |
Company: Boston Scientific |
Recipient: Your Institution |
|
Patents, Royalties, Other Intellectual Property |
No Relationships to Disclose |
|
|
Expert Testimony |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses |
Company: AstraZeneca |
Recipient: You |
|
Other Relationship |
No Relationships to Disclose |
|
|
(OPTIONAL) Uncompensated Relationships |
not answered |
|
|
(OPTIONAL) Open Payments Link |
not answered |
|
|